Finding Precision Through Complexity An AI-powered Biomarker Approach
Finding Precision Through Complexity An AI-powered Biomarker Approach
Sponsored by:
Sponsored by:
More from AI
• By
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
• By
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
• By
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
• By
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
More from Digital Technologies
In partnership with
Learn more about the challenges faced by today’s drug developers and the critical factors to consider as sponsors navigate the supply chain, keep up with regulatory requirements, and ensure patient access. Discover more about the role of generics and how Aspire Pharma can help.
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
In partnership with
Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development